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http://dx.doi.org/10.1016/j.asjsur.20Summary Objective: Esthesioneuroblastoma is an uncommon tumor that is described widely
among the Caucasians. In Singapore, we see predominantly Asian patients with esthesioneur-
oblastomas. From our experience, we note significant and interesting differences between our
data on Asian patients and the published ones on the Caucasian patients.
Methods: A retrospective review of all patients who underwent craniofacial resection for
esthesioneuroblastomas was conducted from January 1997 to January 2010. Relevant data
were collected and statistical analyses were carried out to determine factors that predicted
mortality or complications.
Results: Out of a total of 48 patients who underwent craniofacial resections, half had esthe-
sioneuroblastomas (50%). There was a peak age distribution at the sixth decade of life and
62% of our patients were male. Both local and regional recurrence rate was 50%.
Conclusion: Majority of our Asian patients who underwent craniofacial resections had esthesio-
neuroblastomas. There is a male predilection, and we do not see a bimodal age distribution
that is commonly reported.
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Table 1 Histological diagnosis of patients.
Tumor Number
Esthesioneuroblastoma 24 (50%)
Squamous cell carcinoma 3
Adenocarcinoma 3
Meningioma 3
Clival chordoma 2
Sinonasal undifferentiated carcinoma 2
Adenoid cystic carcinoma 2
Nasopharyngeal carcinoma 1
Basosquamous carcinoma 1
Schwannoma 1
Inverted papilloma 1
Neuroblastoma 1
Recurrent giant cell tumor 1
Leiomyoma 1
Fibrous dysplasia maxillary sinus 1
Renal cell carcinoma metastases
(adenocarcinoma)
1
Total 48
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Esthesioneuroblastoma is an uncommon tumor that was
first reported in 1924 by Berger and Luc.1 With a reported
incidence of 3% for sinonasal neoplasms, there have been
more than 1000 cases reported in the literature, mostly in
the last two decades, but mainly as single case reports or
case series.2 Even large institutions have reported only
relatively small case series over decades, and, as such,
statistical analysis of data was limited. Moreover, most of
these publications are on the Caucasian population. In our
center, which sees predominantly Asian patients for
craniofacial resections, we note significant and interesting
differences between our data and the published ones.
2. Materials and methods
This was a retrospective review of all craniofacial resec-
tions performed in our center, Singapore General Hospital,
from January 1997 to January 2010. Our center is the
largest tertiary hospital in Singapore, which sees predomi-
nantly Asian patients comprising about 74% Chinese,
14% Malays, and 9% Indians of our Singapore population.3
Our unique ethnic distribution allows us to analyze cranio-
facial resection within the Asian ethnicity. We specifically
focused our data analysis on patients diagnosed with
esthesioneuroblastomas.
Preoperatively, most patients will have a computed
tomography (CT) scan of the paranasal sinus to assess bony
invasion to paranasal sinuses or intracranial spread. A
magnetic resonance imaging (MRI) scan is also obtained,
unless the tumor encountered is in an early stage (Kadish
Stage A), so as to assess for intracranial spread accurately
and also to help distinguish between fluid within sinuses
and tumor involvement. Having both modalities of imaging
(CT and MRI scans) will help in more accurate assessment of
staging of tumor.
All patients with esthesioneuroblastomas were then
treated with a dual modality of craniofacial resection
(described below) and adjuvant radiotherapy, as the tumor
is known to be radiosensitive and it improves preservation
of the eye.4,5 Chemotherapy is considered for advanced,
high-grade (Hyams histopathological grade) lesion, as it has
been shown to improve long-term survival.6,7
We categorized postoperative complications into wound-
related (infection, dehiscence, and flap necrosis), central
nervous system (CNS) (cerebrospinal fluid leakage, menin-
gitis, and pneumocephalus), orbital (nasolacrimal duct
obstruction, diplopia, and blindness), and systemic compli-
cations. This categorization was also used by the Interna-
tional Collaborative Study on craniofacial resections and will
help in comparing our data with the large series of data that
has been published thus far.8
Institutional Review Board (IRB) approval was sought
prior to starting this retrospective audit.
2.1. Surgical technique
Most patients were operated on by the same two surgeons
(an otolaryngologist and a neurosurgeon) with the same
open approach. Endoscopic craniofacial resection bya second surgeon was performed only on three patients. An
extended lateral rhinotomy was used for the transfacial
approach to access the tumor intranasally with a bicoronal
incision with periosteal flap used by the neurosurgeons.
After the tumor had been cleared, intraoperative frozen
sections were routinely used for all patients to ensure that
margins were clear prior to conclusion of the operations.
Olfactory bulbs were routinely excised even if they were
not clinically involved to minimize local recurrence rates.
This was because this tumor was known to recur locally
more than 13 years postoperatively despite clear margins of
resections intraoperatively.7 With regard to reconstruction,
neurosurgeons routinely used a vascularized pericranial flap
to close small defects. A temporalis fascia graft was usually
used to augment the closure and a bone calvarium graft
used when the defect was larger. Surgicel and Tisseel glue
were then used to reinforce the closure. All nasolacrimal
ducts were routinely marsupialized to prevent post-
operative epiphora. A flavine-soaked pack was then used to
pack the nasal cavity for 5 days postoperatively. All
patients were then monitored in the neurosurgical inten-
sive care unit (NICU) postoperatively. They were also given
prophylactic intravenous amoxicillineclavulanate for the
first 5 days postoperatively.3. Results
Over a period of 13 years, we had a total of 48 patients who
underwent craniofacial resections. The majority of our
patients had esthesioneuroblastomas (50%) (Table 1). The
rest of the histological diagnoses were a heterogeneous mix
of tumors. Among the patients with esthesioneuro-
blastomas, 22 were Chinese, one was Malay, and one was
Indian. There was a peak incidence in the sixth decade of
life (Fig. 1). We did not see the bimodal peak in age
distribution commonly described in the second and sixth
decade of life.9 A slight male predilection (62% males, 38%
females) was present. The top three commonest symptoms
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Figure 1 Age distribution of patients with esthesioneuro-
blastomas.
Table 3 Postoperative complications.
Complications (number of patients) Details of complications
Wound (n Z 4) Epistaxis
Sinusitis
Stitch granuloma
Nasal valve collapse
Central nervous system (n Z 3) Meningitis
Frontal lobe abscess
Scar epilepsy
Systemic (n Z 2) Urinary tract infection
Atelectasis
Orbital (n Z 1) Epiphora
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other series as well10 (Table 2). One of our patient was
asymptomatic. His condition was diagnosed incidentally
while performing a CT scan of the head for a stable head
injury. We had seven patients with Kadish Stage A, 10
patients with Kadish Stage B, and seven patients with
Kadish Stage C. Hyams histopathological grade was present
in 15 out of 24 patients. Majority (10 out of 15 patients) had
high-grade tumors (Hyams histopathological grade 3 or 4). It
was interesting to note that none of our patients had
cervical lymph nodal metastases at the initial presentation.
Postoperative mortality occurred in one patient (2%).
This patient had multiple comorbidities, with a recent
coronary artery bypass graft 6 months prior to the cranio-
facial resections. He unfortunately sustained a massive
acute myocardial infarction (AMI) on Postoperative Day 9
and passed away later. In our series, two more patients died
from causes unrelated to the tumor. One patient died from
pneumonia 2 years after the initial operation and the other
from a urinary tract infection 5 years after the initial
surgery. Both patients were free of esthesioneuroblastomas
at the time of their death.
Postoperative complication rate occurred in 42% of
patients (Table 3). Wound complications occurred in four
patients (17%). One patient had transient epistaxis on
Postoperative Day 6 after packs were removed, which
resolved spontaneously without intervention. Another one
had sinusitis with mucopus noted in the bilateral middle
meatus, which was treated successfully with antibiotics.
This was possibly from the nasal packing. One patient had
a stitch granuloma that was noted after stitches were
removed on Postoperative Day 8, which also resolved
spontaneously. Another patient had a nasal valve collapse
from the lateral rhinotomy incision that was placed tooTable 2 Clinical symptoms.
Clinical symptoms Number of patients
Epistaxis 19
Blocked nose 11
Rhinorrhea 8
Hyposmia 7
Headache 1
Blood-stained sputum 1
Asymptomatic 1internal in the nares, which was noted 3 months after the
operation. As this was not causing too great a discomfort,
this was not treated further.
CNS complication occurred in three patients (13%). One
patient had a frontal lobe abscess that subsequently
required drainage by the neurosurgeons. This patient
recovered well after the procedure. Another patient sus-
tained meningitis, but, fortunately, this resolved with
intravenous antibiotics. The third patient developed frontal
lobe scar epilepsy that occurred 2 years after the opera-
tion. This patient’s condition was controlled well with
antiepileptic medications.
Systemic complication occurred in two patients (8%).
One patient had a urinary tract infection that occurred on
Postoperative Day 6, and was possibly precipitated by
immobility and the urine catheter present in situ post-
operatively. Antibiotics aborted the infection successfully.
The other patient had pneumonia that occurred on
Postoperative Day 2. This also resolved successfully with
antibiotic therapy.
Orbital complication occurred in one patient (4%). This
patient had epiphora despite marsupialization of the
nasolacrimal duct intraoperatively. This was possibly due to
postoperative edema that compressed the nasolacrimal
duct; fortunately, this resolved spontaneously.
In our series, recurrences (local and regional) occurred
in 12 patients. Patients with regional recurrence all had
cervical lymph nodal involvement, and these patients
subsequently went on to receive a neck dissection. All
patients with local recurrences were fortunately resect-
able, as they were picked up promptly on postoperative
surveillance; they all underwent a revision craniofacial
resection. Fig. 2 shows the disease-specific survival
depending on local, regional, or loco-regional recurrences.
Most of the recurrences occurred within the first year after
the initial operation. Some recurrences (either local or
regional) occurred more than 5 years after the initial
diagnosis. Two out of three patients with both local and
regional recurrences had Hyams histopathological grade 3,
while one of them had Hyams histopathological grade 4
esthesioneuroblastoma.
4. Discussion
Esthesioneuroblastomas are uncommon tumors. As a result,
individual institutions often do not have a significant
Figure 2 Disease-specific survival.
Esthesioneuroblastomas in an Asian population 157number of patients to report meaningful results regarding
survival outcomes and postoperative mortality and compli-
cations. A collaborative study for esthesioneuroblastomas
across multiple centers will be useful in achieving mean-
ingful statistical analyses to increase our understanding of
this disease. Our retrospective study is primarily a descrip-
tive study within a single institution that aims at analyzing
our experience with esthesioneuroblastomas and comparing
our results with overseas institutions.
In our series of craniofacial resections on Asian patients,
50% were diagnosed with esthesioneuroblastomas compared
with 3e12.6% quoted in other institutions’ series of
craniofacial resections.2,8 This is suggestive of a possibly
higher incidence of esthesioneuroblastomas, although
a population-based study would be necessary to confirm
this. Another reason could be that our hospital is a tertiary
center that sees patients from the south-east Asia region,
and this could potentially result in a selection bias. There
was also a male predilection in our series, in contrast with
the female preponderance in several literature published
on the Caucasian population.2 Also, there is a lack of
a bimodal age distribution that is commonly described for
esthesioneuroblastomas.2 Our patients afflicted with this
disease are older, as we do not see patients in the
second decade of life with esthesioneuroblastomas. These
differences may suggest there could be a genetic basis for
the differences between Asian and Caucasian patients
suffering from esthesioneuroblastomas. Preliminary genetic
studies on the tumors have already shown that different
chromosomal alterations may lead to different biological
behavior.4 It could also be extrapolated that Asian patients
may have different genetic subtypes of this disease,
although further genetic studies are needed to confirm this.
Also, a multicenter study within Asia would be helpful in
achieving larger numbers for statistical significance in the
clinical and genetic study of this relatively uncommon
tumor worldwide.
Our postoperative mortality rate of 2% was lower than
the 4.7% quoted for craniofacial resections.8 One patientpassed away from an AMI. He was a high-risk patient who
went for a coronary artery bypass graft just 6 months prior
to his craniofacial resection and, despite preoperative
optimization by the anesthetist, the AMI could not be pre-
vented. Our low mortality rate can be attributed to
a dedicated combined specialty team that is familiar with
patients who undergo neurosurgical treatment. After the
operation, which is just the first step, all patients are
transferred to the NICU whereby dedicated doctors and
nurses trained in monitoring these patients take over. They
are usually kept in the NICU for 5 days postoperatively and
moved to a step-down or high-dependency unit only after
assessment by the two primary surgeons. We had two other
patients who passed away from causes unrelated to
esthesioneuroblastomas. This tumor seems to have a fairly
good prognosis, with no tumor-related mortality in our
series thus far despite either local or regional recurrences.
Most patients can further be treated and can have good
survival subsequently. Two of our patients died of other
diseases and not from the primary disease itself.
Our postoperative morbidity of 42% was comparable to
that quoted in the literature, which varies from 30% to
54%.5e7,10,11 Similar to the classification of postoperative
morbidity by the International Collaborative Study for
craniofacial resections, we classified it into wound-related,
CNS-related, systemic, and orbital-related complications,
as these were the significant complications that could have
happened in our series8 (Table 3). The commonest
complication in our series was wound-related complication,
followed by CNS-related, systemic, and orbital-related
complications. This finding was similar to that of the
International Collaborative Study as well.8
Esthesioneuroblastoma is a disease that is known to
possibly have late recurrences. Therefore, recurrence rate
in any series depends on the duration of follow-up. Our
recurrence rate of 50% over a 13-year period is comparable
to that of data from University of Virginia, which quoted
an overall recurrence rate of 51.3% over a 20-year period.11
The mean follow-up for our patients was 7.3 years. For
esthesioneuroblastomas, the longer the follow-up, the
higher the recurrence rate. The important point to note is
that, despite the recurrences, patients can be treated
adequately to have a good survival prospect subsequently.
None of our patients in this series died from tumor-related
causes despite the recurrences.5. Conclusion
Our study on Asian patients with esthesioneuroblastomas
indicated that the patients tend to be male and in the
older age group. This is different from the female
preponderance in the Caucasian population, where the
patients tend to have a bimodal age distribution, with
a significant proportion being affected in the second
decade of life as well. We also know that craniofacial
resection is a safe procedure for esthesioneuroblastomas
with a low mortality rate. As recurrences can occur several
years after the initial surgery, lifelong postoperative
surveillance of patients is important, and when recur-
rences happen, adequate salvage treatment can ensure
good survivability of patients.
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